Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $45.00 and last traded at $45.0750, with a volume of 36102 shares traded. The stock had previously closed at $43.97.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DNTH shares. Raymond James Financial restated an “outperform” rating and set a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Truist Financial assumed coverage on Dianthus Therapeutics in a report on Tuesday, October 14th. They set a “buy” rating and a $56.00 price target on the stock. Stifel Nicolaus boosted their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim increased their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $63.43.

Dianthus Therapeutics Stock Performance

The firm has a market cap of $1.90 billion, a P/E ratio of -12.72 and a beta of 1.56. The firm’s fifty day simple moving average is $37.71 and its 200 day simple moving average is $27.97.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 236,538 shares of company stock valued at $8,983,175 over the last quarter. Corporate insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. US Bancorp DE lifted its position in Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after buying an additional 1,510 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the period. Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics during the third quarter worth $64,000. Finally, Tower Research Capital LLC TRC increased its position in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.